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Abstract
Background: Allergic asthma is on the rise in developed countries. A common characteristic of allergens is that they 
contain intrinsic protease activity, and many have been shown to activate protease-activated receptor (PAR)-2 in vitro. 
The role for PAR-2 in mediating allergic airway inflammation has not been assessed using a real world allergen.
Methods: Mice (wild type or PAR-2-deficient) were sensitized to German cockroach (GC) feces (frass) or protease-
depleted GC frass by either mucosal exposure or intraperitoneal injection and measurements of airway inflammation 
(IL-5, IL-13, IL-17A, and IFNγ levels in the lung, serum IgE levels, cellular infiltration, mucin production) and airway 
hyperresponsiveness were performed.
Results: Following systemic sensitization, GC frass increased airway hyperresponsiveness, Th2 cytokine release, serum 
IgE levels, cellular infiltration and mucin production in wild type mice. Interestingly, PAR-2-deficient mice had similar 
responses as wild type mice. Since these data were in direct contrast to our finding that mucosal sensitization with GC 
frass proteases regulated airway hyperresponsiveness and mucin production in BALB/c mice (Page et. al. 2007 Resp Res 
8:91), we backcrossed the PAR-2-deficient mice into the BALB/c strain. Sensitization to GC frass could now occur via the 
more physiologically relevant method of intratracheal inhalation. PAR-2-deficient mice had significantly reduced airway 
hyperresponsiveness, Th2 and Th17 cytokine release, serum IgE levels, and cellular infiltration compared to wild type 
mice when sensitization to GC frass occurred through the mucosa. To confirm the importance of mucosal exposure, 
mice were systemically sensitized to GC frass or protease-depleted GC frass via intraperitoneal injection. We found that 
removal of proteases from GC frass had no effect on airway inflammation when administered systemically.
Conclusions: We showed for the first time that allergen-derived proteases in GC frass elicit allergic airway 
inflammation via PAR-2, but only when allergen was administered through the mucosa. Importantly, our data suggest 
the importance of resident airway cells in the initiation of allergic airway disease, and could make allergen-derived 
proteases attractive therapeutic targets.
Introduction
Allergic asthma is a chronic airway disorder character-
ized by airway inflammation, increased airway reactivity,
and increased mucus production. While there is a genetic
predisposition for asthma, this cannot account for the
significant increase in asthma prevalence over the past 20
years. Environmental factors, including house dust mite
(HDM) and cockroach (CR) exposure [1], play a signifi-
c a n t  r o l e  i n  a l l e r g i c  a i rw a y  d i s e a s e .  O n e  c h a r a c t e r i s t i c
that many of these allergens, including cockroach, HDM,
fungi, pollen and cat [2-7] contain proteolytic activity.
The mechanism by which proteases modulate the
immune system to initiate or maintain allergic airway dis-
ease is currently unclear.
W e  r e c e n t l y  a d d r e s s e d  t h e  r o l e  o f  a c t i v e  s e r i n e  p r o -
teases in GC frass on regulating allergic airway inflamma-
t i o n  i n  a  m u r i n e  m o d e l .  W e  f o u n d  t h a t  a i r w a y
hyperresponsiveness to acetylcholine and mucin produc-
tion were significantly decreased when mice were
exposed to protease-depleted GC frass compared to pro-
tease-containing GC frass [8]. Other studies have sup-
ported the role of proteases in modulating allergic airway
disease. For example, removal of proteases from either A.
fumigatus [9], American cockroach Per a 10 antigen [10],
Epi p1 antigen from the fungus Epicoccum purpurascens
[11]or Cur 11 antigen from the mold Curvularia Iunata
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[12] decreased airway inflammation and airway hyperre-
sponsiveness in mouse models. These studies did not
investigate mechanism(s) by which proteases mediated
their effects.
Some reports have shown that protease activity in aller-
gens may alter airway epithelial integrity by increasing
epithelial permeability [13,14]. However, the proteases
can also mediate biological effects through the activation
of protease-activated receptors (PARs). PARs (-1, -2, -3, -
4) are a family of proteolytically activated G-coupled
receptors which, when activated, initiate a signal trans-
duction pathway leading to transcriptional regulation. Of
particular interest is PAR-2, which has been implicated in
allergic diseases. PAR-2 is expressed by many cells in the
lung, including airway epithelial cells [15], alveolar mac-
rophages [16], fibroblasts [17], and mast cells [18]. Com-
mon allergens including HDM, cockroach and mold have
been shown to activate PAR-2, resulting in increased
cytokine production by airway epithelial cells [15,19,20].
Recently, activation of PAR-2 was also shown to increase
the expression of thymic stromal lymphopoietin (TSLP)
[21], which activates dendritic cells to polarize naïve T
cells to Th2 cells. Collectively, these data suggest that
proteases, through their activation of PAR-2, may link the
innate and adaptive immune responses.
To date, only a few studies have investigated the impor-
tance of PAR-2 in modulating allergic airway disease.
Mice sensitized and challenged with ovalbumin (OVA)
along with PAR-2 activating peptides promoted allergic
sensitization [22]. Sensitization by intraperitoneal injec-
t io n of  O V A bo und t o al um  f ol low ed by O V A a er osol
challenge showed that PAR-2-deficient mice had less cel-
lular infiltration than wild type mice [23]. In the same
study, mice which overexpressed PAR-2 when sensitized
and challenged with OVA showed an increase in AHR
compared to wild type mice. These studies suggest that
PAR-2 may act as an adjuvant in allergic airway disease.
Importantly though, these studies investigated the effect
of PAR-2 activation following systemic (OVA-induced)
inflammation. In this report, we investigate the role of
PAR-2 activation by a real world, protease-containing
allergen and we will investigate the role of proteases in
the initiation of allergic responses.
Materials and methods
Cockroach frass
Fecal remnants (frass) were collected from German cock-
roaches (Blattella germanica) and reconstituted as previ-
ously described [24]. The frass preparation was frozen in
aliquots and used throughout the entire experiment. Pro-
tease levels were measured by Azocoll assay and deter-
mined to be 19 μg/mg frass [25]. Azocoll is an insoluble
protein-dye conjugate hydolysed by serine proteases [26].
A standard curve was generated by digestion of Azocoll
with known concentrations of subtilisin (Type VIII pro-
tease, Sigma Chemical, St. Louis MO). We found that
treatment with serine protease inhibitors aprotinin and
PMSF inhibited GC frass protease activity by 80%, while
cysteine protease inhibitors E64 and leupeptin had no
effect [2].
Animals
Balb/c and PAR-2-deficient mice were obtained from
Jackson Laboratory (Bar Harbor, ME). The PAR-2-defi-
cient mice were on the C57BL/6 background, which has
been documented to be the least responsive to allergen
exposure via the airway [8,27], thus necessitating the
need to backcross these mice onto the Balb/c back-
ground. ThePAR-2 mice used in this study are on the
Balb/c background. These studies conformed to the prin-
ciples for laboratory animal research outlined by the Ani-
mal Welfare Act and the Department of Health,
Education, and Welfare (National Institutes of Health).
These studies were approved by the Cincinnati Children's
Hospital Medical Center Institutional Animal Care and
Use Committee.
Sensitization and challenge protocols
For systemic allergen sensitization, mice were immunized
with PBS or 10 μg/ml GC frass bound to alum (Imject
Alum; Pierce Biotechnology, Rockford, IL) on day 0 and 7,
followed by intratracheal inhalation challenges with GC
frass (40 μg/40 μl) on days 14 and 19. Mice were har-
vested on day 22 (Figure 1A). Intratracheal inhalations
are performed on anesthetized mice (45 mg/kg ketamine
and 8 mg/kg xylazine) suspended on a 60 degree incline
board. With the tongue gently extended, a 40 μl aliquot of
PBS or GC frass is placed in the back of the oral cavity
and aspirated by the mouse [27]. For airway administra-
tion of allergen, mice were given three intratracheal inha-
lation challenges of PBS (40 μl) or GC frass (40 μg/40 μl)
on days 0, 7, and 14 and harvested on day 17 (Figure 1B).
Airway hyperresponsiveness measurements
Allergen-induced AHR was determined as we have previ-
ously described [28]. Briefly, mice were anesthetized 72
Figure 1 Sensitization and challenge protocols. A. Mucosal aller-
gen sensitization. B. Systemic allergen sensitization.Page et al. Respiratory Research 2010, 11:62
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hours after the last GC frass exposure, intubated and ven-
tilated at a rate of 120 breaths per minute with a constant
tidal volume of air (0.2 ml), and paralyzed with decame-
thonium bromide (25 mg/kg). After establishment of a
stable airway pressure, 25 μg/kg weight of acetylcholine
was injected i.v. and dynamic airway pressure (airway
pressure time index [APTI] in cm-H2O × sec-1) was fol-
lowed for 5 minutes.
Serum IgE
Animals were bled and serum isolated for total IgE levels
using antibodies from BD Biosciences (San Diego, CA).
Assessment of airway inflammation
Lungs were lavaged thoroughly with 1 ml of Hanks bal-
anced salt solution without calcium or magnesium. The
lavage fluid was centrifuged (1,800 rpm for 10 min), the
supernatant was removed for cytokine analysis and
immediately stored at -80°C. Total cell numbers were
counted on a hemocytometer. Slides of BAL cells were
prepared using a Cytospin II (Shandon Thermo,
Waltham, MA) and were stained with Diff-Quick
(Thermo Electron Corporation, Pittsburg, PA) solution
for differential cell counting.
Cytokine production
Liberase/DNase I digests of the lung were prepared to
obtain single lung cell suspensions. Single cell suspen-
sions (2.5 × 105) were incubated for 72 hours in culture
medium (RPMI) or in RPMI treated with Conconavalin A
(ConA; 10 μg/ml) and supernatants were analyzed by
ELISA for Th2 cytokine expression as previously
described [29]. IL-17A levels were determined in media
without ConA.
Histology
Whole lungs were removed and formalin fixed. Lungs
were embedded in paraffin, sectioned, and stained with
haematoxylin and eosin (H & E) and Periodic Acid Schiff
(PAS). To quantify mucin production, we counted air-
ways and determined the percentage of mucin stained
airways (mean ± SEM; n = 3 slides per condition). Next,
we picked representative airways and counted total and
mucin positive cells in that airway and determined the
percentage of mucin positive cells (mean ± SEM; n = 5
airways per condition).
Statistical analysis
When applicable, statistical significance was assessed by
one-way analysis of variance (ANOVA). Differences iden-
tified by ANOVA were pinpointed by Student-Newman-
Keuls' multiple range test.
Results
PAR-2-deficient mice sensitized with GC frass by 
intraperitoneal injection does not alter experimentally-
induced asthma in a mouse model
To determine the role of PAR-2 in mediating experimen-
tally-induced allergic airway inflammation, we used com-
mercially available PAR-2-deficient mice which were on a
C57Bl/6 background. Since C57Bl/6 mice are the least
responsive mice and do not respond well to sensitization
by intratracheal inhalation [8,27], we performed the sen-
sitization by intraperitoneal injection of GC frass bound
to alum and then challenged mice via intratracheal inha-
lation (Figure 1A). In the wild type mice, GC frass signifi-
cantly increased airway responsiveness to cholinergic
agents (Figure 2A), increased serum IgE levels (Figure
2B), and increased the Th2 cytokines IL-5 and IL-13 (Fig-
ure 2C and 2D). Importantly, in the PAR-2-deficient mice,
there was no significant alteration of any airway inflam-
matory parameters tested. GC frass induced significant
recruitment of macrophages, eosinophils, neutrophils
and lymphocytes into the BAL fluid (Table 1); however
these levels were unaltered in PAR-2-deficient mice. His-
tological examination of the wild type or PAR-2-deficient
mouse lungs following GC frass treatment showed dense
perivascular and peribronchiolar infiltrates compared to
PBS treatment (data not shown). The levels of cellular
infiltrates were not different between wild type or PAR-2-
deficient mice following GC frass exposure. In addition,
abundant mucin was detected in the epithelial cells of
wild type and PAR-2-deficient mice exposed to GC frass
(data not shown). Importantly, PAR-2-deficiency had no
significant effect on any of the parameters tested, sug-
gesting that PAR-2 did not play a role in mediating aller-
gic airway inflammation. This finding was in conflict with
our previous study showing that GC frass proteases
played a role in regulating airway hyperresponsiveness
and mucin production [8]. Interestingly both our lab [30]
and others [31] have shown that GC frass proteases
cleave and activate PAR-2 in vitro; thus it is possible that
the route of sensitization is an important factor in pro-
tease-PAR-2 mediated allergic airway inflammation.
PAR-2-deficient mice sensitized with GC frass by 
intratracheal inhalation attenuated experimentally-
induced asthma in a mouse model
To investigate the role of PAR-2 in allergic airway inflam-
mation when administered via the airways, we back-
crossed the PAR-2-C57Bl/6 mice into the BALB/c
background. Mucosal sensitization of GC frass was per-
formed in wild type and PAR-2-deficient mice by admin-
istration of three inhalations of allergen or PBS (Figure
1B). Exposure of wild type mice to GC frass resulted in
increased airway responsiveness to cholinergic agentsPage et al. Respiratory Research 2010, 11:62
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which were significantly decreased in the PAR-2-deficient
mice (Figure 3A). Serum IgE levels, which were signifi-
cantly increased following exposure to GC frass, were
also regulated through PAR-2 activation (Figure 3B).
Next, we cultured whole lung homogenates from wild
type and PAR-2-deficient mice to assess the ability of GC
frass to induce Th2 (IL-4, IL-5 and IL-13), Th1 (IFNγ),
and Th17 (IL-17A) cytokine production. GC frass signifi-
cantly increased IL-13 (Figure 3C), IL-5 (Figure 3D), IL-4
(data not shown), and IL-17A (Figure 3E) levels. Impor-
tantly, all of these cytokines were significantly reduced in
PAR-2-deficient mice compared to wild type mice. In
addition, GC frass reduced the levels of IFNγ in both wild
type and PAR-2-deficient mice (Figure 3F). Cellular infil-
tration into the BAL fluid was also significantly different
between wild type and PAR-2-deficient mice. Exposure to
GC frass resulted in significant recruitment of eosino-
phils, neutrophils, macrophages and lymphocytes in wild
type mice (Table 2). PAR-2-deficient mice had signifi-
cantly less eosinophils, neutrophils and macrophages in
the BAL fluid compared to wild type mice. Histological
examination of the wild type or PAR-2-deficient mouse
lungs following GC frass treatment showed dense
perivascular and peribronchiolar infiltrates compared to
PBS treatment (Figure 4). There was a notable decrease in
the amount of infiltration of cells into the airways of PAR-
2-deficient mice compared to wild type mice. GC frass-
treated airways had more mucin than PBS-treated mice
(Figure 5). While the number of airways possessing
mucin were comparable between wild type and PAR-2-
deficient mice (67 ± 2 airways in wild type mice and 69 ±
1), the amount of cells expressing mucin was different. In
the airways of wild type mice, 90.3 ± 3.2% of the cells
expressed mucin while in the PAR-2-deficient mice only
72.5 ± 5% of the cells expressed mucin (p = 0.013 as deter-
mined by ANOVA). Collectively, these data indicate a
role for PAR-2 in mediating GC frass-induced allergic air-
way inflammation.
GC frass proteases are crucial in the initiation phase of 
experimental asthma
Our recently published data showed that mucosal sensiti-
zation to protease-depleted GC frass resulted in
decreased airway hyperresponsiveness and decreased
mucin production [8]. To define the role of GC frass pro-
teases in modulating allergic airway disease, we asked if
protease-depleted GC frass would play a role in systemic
a l l e r g i c  s e n s i t i z a t i o n .  T o  d o  t h i s ,  m i c e  w e r e  s e n s i t i z e d
with GC frass or protease-depleted GC frass bound to
alum via intraperitoneal injection (Figure 1A). These
mice were then challenged with an intratracheal inhala-
tion of either GC frass or protease-depleted GC frass on
day 14 and 19. On day 22, mice were sacrificed and aller-
gic airway inflammation and airway hyperresponsiveness
were assessed. As expected, GC frass induced airway
hyperreactivity to acetylcholine, serum IgE levels, Th2
cytokines, cellular influx and mucin production (Figure
6). Importantly, removal of GC frass proteases had no
effect on airway hyperreactivity (Figure 6A), Th2
c y t o k i n e  p r o d u c t i o n  ( F i g u r e s  6 C  a n d  6 D ) ,  o r  T h 1
cytokine production (Figure 6F). IL-17 was not induced
in these mice in this sensitization protocol by GC frass
(Figure 6E). We also found that removal of proteases sig-
nificantly decreased GC frass-induced serum IgE levels
(Figure 6B). GC frass induced significant recruitment of
macrophages, eosinophils, neutrophils and lymphocytes
into the BAL fluid; however these levels were unaltered
when mice were sensitized to protease-depleted GC frass
(data not shown). Histological examination of the mouse
lungs following GC frass treatment showed dense
perivascular and peribronchiolar infiltrates compared to
PBS treatment (Figure 7). Depletion of proteases from
GC frass had little effect on the amount of perivascular
Table 1: Differential cell count in BAL fluid of wild type and PAR-2-deficient mice.
Mac Epi Eos Neut Lymph
C57-PBS 5.2 ± 1.0 5.5 ± 1.9 0.03 ± 0.02 0.02 ± 0.01 0.09 ± 0.03
PAR2-/- PBS 5.1 ± 1.4 7.3 ± 2.4 0.04 ± 0.02 0.05 ± 0.02 0.1 ± 0.04
C57-frass 35.1 ± 11 16.9 ± 7.1 11.7 ± 3.4 17 ± 7.9 23.4 ± 7.9
PAR2-/- frass 32.8 ± 9.9 8.6 ± 4.2 19.2 ± 5.6 14.1 ± 6.7 21.0 ± 7.0
Wild type (C57Bl/6) or PAR-2-deficient mice were given intraperitoneal injections of PBS or GC frass with alum on day 0 and 7. Intratracheal 
inhalations of PBS or GC frass were performed on days 14 and 19. On day 22, BAL fluid was harvested and differential cell counts performed. 
These data represent 9 mice per group and are expressed as mean ± SEM of cell number × 104. Cell counts were statistically significant 
between GC frass and PBS exposed mice (*p < 0.05, as determined by ANOVA). There was no statistically significant difference between mice 
C57Bl/6 and PAR-2-deficient mice exposed to GC frassPage et al. Respiratory Research 2010, 11:62
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and peribronchiolar infiltrates compared to GC frass
treatment. While GC frass significantly increased the
amount of mucin, we could not detect any significant dif-
ferences in the amount of mucin between GC frass and
protease-depleted GC frass (Figure 8). Collectively, these
data show that the proteases associated with allergens do
not regulate allergic sensitization when they are adminis-
tered systemically, highlighting the importance of the res-
ident airway cells (airway epithelium and alveolar
macrophages) in the initiation of allergic airway disease.
Discussion
In this study, we investigated the role of PAR-2 in mediat-
ing allergic airway inflammation using a real world aller-
gen. Our initial experiments showed that GC frass-
induced allergic airway inflammation was unaltered in
PAR-2-deficient mice compared to wild type mice. At
first blush, this might suggest that GC frass proteases
were altering allergic airway inflammation independent
of PAR-2. However, a crucial difference between the stud-
ies in BALB/c mice and C57Bl/6 mice was the method of
sensitization (mucosal vs. systemic) and the use of the
Th2 stimulator alum. The commercially available PAR-2-
knockout mice were in the C57Bl/6 background; one that
we have previously shown is not highly responsive to
mucosal sensitization [8,27], and thus required systemic
sensitization with alum. To directly study the effect of GC
frass protease on mucosal sensitization of PAR-2-defi-
cient mice, we backcrossed the PAR-2-deficient mice
onto the BALB/c strain. Mucosal exposure of GC frass to
PAR-2-deficient BALB/c mice resulted in diminution of
all aspects of allergic airway inflammation compared to
Figure 2 GC frass-induced experimental allergic asthma in C57/BL6 wild type and PAR-2-deficient mice. Wild type and PAR-2-deficient mice 
were sensitized on day 0 and 7 with an intraperitoneal injection of 100 ug/ml PBS or GC frass with alum (10 μg/ml). On days 14 and 19, an intratracheal 
inhalation was performed using PBS (40 μl) or GC frass (40 μg). On day 22, mice were anesthetized acetylcholine was injected after establishment of 
a stable airway pressure. In all cases the data are expressed as mean ± SEM and represent 9-10 mice per group and statistical significance determined 
by ANOVA. A. AHR was measured as airway pressure time index (APTI) in cm-H2O × sec -1 (compared to PBS *p < 0.001 and ** = 0.016). B. Serum IgE 
levels were analyzed by ELISA (compared to PBS *p < 0.001, **p = 0.002). C+D. Lungs from the mice were excised, and cells dissociated and maintained 
in a single suspension culture for 3 days in the presence of Con A (10 μg/ml). Supernatants were removed and ELISAs were run. C. IL-5 levels (compared 
to PBS *p < 0.001). D. IL-13 levels (compared to PBS *p < 0.001).
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wild type mice. Together these data confirmed the impor-
tance of PAR-2 in the initiation of allergic airway disease
when sensitization occurred at the mucosal surface.
In an attempt to clarify the importance of proteases
administered at the mucosa compared to systemically, we
compared GC frass with and without protease activity
during systemic sensitization. We found that systemic
sensitization with protease-depleted GC frass did not
alter airway inflammation or AHR compared to protease-
containing GC frass, suggesting that removal of proteases
are not important when sensitization occurs systemically.
However, in order to perform these experiments we had
to bind the allergen to alum, so we cannot fully rule out
the possibility that alum may overwhelm the immunos-
timulatory effects of protease activity in GC frass. None-
theless, the idea that proteases would play a contributory
role at the epithelium fits in well with literature demon-
strating a role for PAR-2 and proteases in epithelial cell
Table 2: Differential cell count in BAL fluid of wild type and PAR-2-deficient mice.
Mac Epi Eos Neut Lymph
Balb/c-PBS 0.9 ± 0.4 1.8 ± 0.6 0 0.04 ± 0.02 0.07 ± 0.06
PAR2-/- PBS 2.0 ± 0.7 3.0 ± 1.2 0 0.02 ± 0.02 0.04 ± 0.02
Balb/c-frass 7.8 ± 0.9* 5.2 ± 1.1 4.7 ± 1.3* 5.9 ± 3.9* 2.9 ± 0.7*
PAR2-/- frass 3.8 ± 0.9** 3.1 ± 1.2 1.7 ± 0.8** 0.8 ± 0.2** 2.3 ± 0.9*
Wild type (Balb/c) or PAR-2-deficient mice were given intratracheal inhalations of PBS (40 μl) or GC frass (40 μg/40 μl) on days 0, 7, and 14. On 
day 17, BAL fluid was harvested and differential cell counts performed. These data represent 4 mice per group and are expressed as mean ± 
SEM of cell number × 104. Cell counts were statistical significance between GC frass and PBS exposed mice (*p < 0.05, as determined by 
ANOVA). In addition, statistical differences were found between Balb/c and PAR-2-deficient mice exposed to GC frass (**p < 0.05).
Figure 3 GC frass-induced experimental allergic asthma in wild type and PAR-2-deficient mice. Balb/c wild type and PAR-2-deficient mice were 
challenged by intratracheal inhalation on day 0, 7, and 14 with PBS or GC frass (40 μg). On day 17, mice were anesthetized and acetylcholine was in-
jected after establishment of a stable airway pressure. In all cases the data are expressed as mean ± SEM and represent 4-5 mice per group and statis-
tical significance determined by ANOVA. A. AHR was measured as airway pressure time index (APTI) in cm-H2O × sec -1 (compared to PBS * p < 0.001, 
compared to GC frass **p = 0.014). B. Serum IgE levels were analyzed by ELISA (compared to PBS *p = 0.011, compared to GC frass **p = 0.024). C-F. 
Lungs from the mice were excised; cells dissociated and maintained in a single suspension culture for 3 days in the presence of Con A (10 μg/ml). C. 
IL-13 levels (compared to PBS *p < 0.001, **p = 0.004, compared to GC frass ***p = 0.041). D. IL-5 levels (compared to PBS *p < 0.001, compared to GC 
frass **p = 0.004). E. IL-17A levels F. IFNγ levels (compared to PBS *p < 0.05).
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activation. Cockroach [30,32] ,  H D M [ 3 ]  a n d  m o l d  [ 2 0 ]
proteases have all been shown to induce IL-8 expression
from cultured airway epithelial cells in a PAR-2-depen-
dent manner. The idea that alteration of the epithelium
can initiate allergic airway disease has been eloquently
shown in the studies by Pantano et. al. [33]. They showed
that upregulation of NF-κB in the airway epithelium of
transgenic mice without any other stimulus was sufficient
for AHR and smooth muscle thickening. These data sug-
gest the crucial role of the airway epithelium in asthma
pathogenesis, and lends support to our data that pro-
teases administered via the airways can ultimately modu-
late airway inflammation and AHR.
Interestingly protease-depleted GC frass bound to
alum and administered by intraperitoneal injection
decreased total serum IgE levels. We did not assay for GC
frass-specific IgE or aprotinin-specific IgE in this study.
The regulation of serum IgE levels may be due to protease
activity or may be a non-specific effect. Aprotinin was
widely used to prevent bleeding and reduce blood trans-
fusions after surgical procedures until it was shown that
the use of aprotinin was associated with doubling the risk
of renal failure in patients undergoing heart surgery [34].
There is at least one report showing a severe anaphylactic
reaction with highly elevated IgE levels after a single
exposure to aprotinin in a young child [35]. In our stud-
ies, aprotinin alone increased IgE; however aprotinin-
treated GC frass was shown to decrease serum IgE. Since
aprotinin-treated GC frass administered systemically had
no effects other than on serum IgE levels, we have not fol-
lowed up on this finding.
C57Bl/6 mice have been shown to be the least respon-
sive to systemic OVA allergen exposure [36,37] and were
not very responsive to GC frass when exposed at the
mucosa [38]. However it was recently demonstrated that
HDM allergen induced Th2 cytokines, eosinophil infiltra-
tion and AHR in C57Bl/6 mice [39]. It is likely that OVA,
HDM and GC frass differ in their adjuvant properties or
even in their pathogen-associated molecular patterns
(PAMPs), both of which can alter allergenicity. In addi-
tion, there is new information suggesting that the coloni-
zation of the gastrointestinal tract of mice can play a role
in the immune response [40]. These exciting data could
potentially explain slightly different immunological
responses found in different labs. At this point it is
unclear why different strains of mice are more or less sus-
ceptible to allergic airway inflammation. It has been
shown that certain mouse strains have a genetic predis-
position to a Th1 or Th2 response which appears to be
independent of provocation. For example, C57Bl/6 mice
tend to mount Th1 immune responses, while BALB/c
mice tend to mount a Th2 response [41] as evidenced by
the finding that C57Bl/6 mice can clear Leishmania major
infection in a Th1-mediated fashion, while BALB/c mice
have a Th2 response [42]. The predisposition to mount
either a Th1 or Th2 response may also be a factor in aller-
gic asthma in humans as well.
We cannot rule out the possibility that asthma genes
surround the PAR-2 locus that may have been introduced
into the BALB/c mice when we backcrossed the PAR-2
locus into that strain of mice. All genes encoding PARs
map to chromosome 13D2 in mouse and 5q13 in humans
Figure 4 Histological assessment of lung sections from PBS or GC 
frass exposed wild type and PAR-2-deficient Balb/c mice. Haema-
toxylin and eosin (H&E) staining of sectioned lungs from PBS (A and B) 
or GC frass (C and D) treated wild type (A and C) or PAR-2-deficient (B 
and D) mice. Representative slides are shown of sections from 4-5 mice 
per group.
Figure 5 Histological assessment of mucin staining from PBS or 
GC frass exposed wild type or PAR-2-deficient Balb/c mice. Period-
ic Acid Schiff (PAS) staining of sectioned lungs from PBS (A and B) or GC 
frass (C and D) treated wild type (A and C) or PAR-2-deficient (B and D) 
mice. Representative slides are shown of sections from 4-5 mice per 
group.Page et al. Respiratory Research 2010, 11:62
http://respiratory-research.com/content/11/1/62
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Figure 6 GC frass proteases do not regulate airway inflammation and airway hyperresponsiveness. BALB/c mice were sensitized on day 0 and 
7 with an intraperitoneal injection of PBS, aprotinin-treated PBS, GC frass, or GC frass pretreated with aprotinin (10 μg/ml) and then bound to alum. 
On days 14 and 19, an intratracheal inhalation was performed using PBS, PBS pretreated with aprotinin, GC frass (40 μg) or GC frass pretreated with 
aprotinin. On day 22, mice were anesthetized acetylcholine was injected after establishment of a stable airway pressure. In all cases the data are ex-
pressed as mean ± SEM and represent 8 mice per group and statistical significance determined by ANOVA. A. AHR was measured as airway pressure 
time index (APTI) in cm-H2O × sec -1 (compared to PBS * p < 0.001). B. Serum IgE levels were analyzed by ELISA (compared to PBS *p < 0.001, compared 
to GC frass **p < 0.002). C-F. Lungs from the mice were excised, and cells dissociated and maintained in a single suspension culture for 3 days in the 
presence of Con A (10 μg/ml). C. IL-5 levels (compared to PBS *p < 0.05). D. IL-13 levels (compared to PBS *p < 0.001). E. IL-17A levels. F. IFNγ levels 
(compared to PBS *p < 0.05).
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Figure 7 Histological assessment of lung sections from mice ex-
posed to GC frass or protease-depleted GC frass. Haematoxylin and 
eosin (H & E) staining of sectioned lungs mice exposed to PBS (A), apro-
tinin-treated PBS (B), GC frass (C) or protease-depleted GC frass (D). 
Representative slides are shown of sections from 8 mice per group.
Figure 8 Histological assessment of mucin staining from mice ex-
posed to GC frass or protease-depleted GC frass. Periodic Acid 
Schiff (PAS) staining of sectioned lungs from mice exposed to PBS (A), 
aprotinin-treated PBS (B), GC frass (C) or protease-depleted GC frass (D). 
Representative slides are shown of sections from 8 mice per group.Page et al. Respiratory Research 2010, 11:62
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[43]. A very recent report showed that chromosome 13 in
mice played a role in AHR and they found 29 candidate
genes of interest [44]. Human chromosome 5 has also
been implicated to contribute to asthma as both IgE and
IL-4 are found on 5q31.1 [45]. However, since protease-
depleted GC frass decreased AHR and mucin production
in wild type mice [8] similar to our findings with the PAR-
2 backcrossed mice, we feel that it is unlikely that our
effects are due solely to asthma genes surrounding the
PAR-2 locus.
This is the first to address the role of PAR-2 in mediat-
ing allergic airway inflammation and AHR using a physi-
ologically relevant allergen administered in a
physiologically relevant manner. A few groups have
explored the role of PAR-2 in mediating airway inflam-
mation and AHR using either PAR-2-deficient mice or
PAR-2 activating peptides. Schmidlin et. al. showed that
systemic sensitization to OVA in PAR-2-deficient mice
resulted in decreased cellular infiltration and a trend
towards decreased airway hyperresponsiveness [23].
Another group sensitized mice with OVA and then chal-
lenged with OV A in the presence or absence of P AR-2
activating peptides showed an increase in airway inflam-
mation and reactivity [46]. In contrast, it was also shown
that activation of PAR-2 reduced airway inflammation in
a rabbit model of experimental asthma [47]. In that study,
they sensitized mice to pollen and then aerosol chal-
lenged rabbits with allergen in the presence or absence of
PAR-2 activating peptides and found that PAR-2 activa-
tion decreased airway reactivity. The conflicting effects of
PAR-2 could be due to timing of the activation of PAR-2,
for example in both studies PAR-2 was administered dur-
ing the effector phase of allergic disease. Using a physio-
logically relevant method of exposure, we highlight the
importance of mucosal sensitization in this process.
These data also suggest the role of allergen-derived pro-
teases as an adjuvant in the development of allergic air-
way disease.
List of Abbreviations
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